Suchergebnisse - "Pinato, David J"

PubPharm (95)

1

Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer

enthalten in: JAMA oncology | 2019

von Pinato, D. | Howlett, S. | Ottaviani, D. | +18

ErratumIn: JAMA Oncol. 2020 Feb 1;6(2):302. - PMID 32053159

2

Antibiotic therapy and outcome from immune-checkpoint inhibitors

enthalten in: Journal for immunotherapy of cancer | 2019

von Pinato, D. | Gramenitskaya, D. | Altmann, D. | +4

3

Antibiotic therapy and outcome from immune-checkpoint inhibitors

enthalten in: Journal for ImmunoTherapy of Cancer | 2019

von Pinato, D. | Gramenitskaya, D. | Altmann, D. | +4

4

Antibiotic therapy and outcome from immune-checkpoint inhibitors

enthalten in: Journal for ImmunoTherapy of Cancer | 2019

von Pinato, D. | Gramenitskaya, D. | Altmann, D. | +4

5

The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2019

von Sanghera, C. | Teh, J. | Pinato, D.

6

Therapeutic hierarchy in hepatocellular carcinoma : A dispute of evidence versus practice

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2019

von Pinato, D.

CommentOn: Liver Int. 2019 Aug;39(8):1478-1489. - PMID 31131974

7

Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma

enthalten in: European journal of cancer (Oxford, England : 1990) | 2019

von Howell, J. | Atkinson, S. | Pinato, D. | +11

8

Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib : A Propensity Score Analysis

enthalten in: Liver cancer | 2019

von Bettinger, D. | Pinato, D. | Schultheiss, M. | +24

CommentIn: Strahlenther Onkol. 2019 Feb;195(2):188-189. - PMID 30552450

9

Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

enthalten in: Hepatology (Baltimore, Md.) | 2019

von Flynn, M. | Sayed, A. | Sharma, R. | +2

10

Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma : the Blueprint-HCC study

enthalten in: British journal of cancer | 2019

von Pinato, D. | Mauri, F. | Spina, P. | +12

1
2
3
4
5
6
7
8
9
10
Nächster »
[10]